High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide.

Roberge, M; Berlinck, R G; Xu, L; Anderson, H J; Lim, L Y; Curman, D; Stringer, C M; Friend, S H; Davies, P; Vincent, I; Haggarty, S J; Kelly, M T; Britton, R; Piers, E; Andersen, R J

Roberge, M; Berlinck, R G; Xu, L; Anderson, H J; Lim, L Y; Curman, D; Stringer, C M; Friend, S H; Davies, P; Vincent, I; Haggarty, S J; Kelly, M T; Britton, R; Piers, E; Andersen, R J.

Affiliation

Roberge M; Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, Canada. michel@otter.biochem.ubc.ca

Cancer Res ; 58(24): 5701-6, 1998 Dec 15.

Article in En | MEDLINE | ID: mdl-9865726

Subject(s)

DNA Repair; G2 Phase; Imidazoles/isolation & purification; Indoles/isolation & purification; Radiation-Sensitizing Agents/isolation & purification; Adenocarcinoma; Animals; Breast Neoplasms; Genes, p53; Humans; Imidazoles/chemistry; Imidazoles/pharmacology; Indoles/chemistry; Indoles/pharmacology; Lung Neoplasms; Staurosporine/chemistry; Succinimides/chemistry; Tumor Cells, Cultured

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Radiation-Sensitizing Agents / G2 Phase / DNA Repair / Imidazoles / Indoles Type of study: Diagnostic_studies Limits: Animals / Humans Language: En Year: 1998 Type: Article

Search on Google

XML

PubMed Links